

Special Issue

Recent Advances in Therapeutic Cancer Vaccines and their Outcomes

Message from the Guest Editors

Vaccine targets are selected based on several factors, including the tumor microenvironment, which plays an important role in the clinical outcome. Immunotherapies that engage both the adaptive and innate immune systems have the potential to enhance cancer therapeutics. This Special Issue will focus on recent advances in therapeutic cancer vaccines and their outcomes. Specifically, we will look at how the antigen repertoire for vaccine targets can be improved and expanded, consider new developments in vaccine platforms, and explore in situ vaccines. The Special Issue will explore the identification of biomarkers for cancer prognosis and evaluate the mechanism of action and adverse effects associated with antigen targeting. Other potential topics include:

- Combining vaccine platforms with novel immunomodulatory approaches.
- Treatments for overcoming tumor resistance and enhancing clinical efficacy.
- Adoptive transfer therapy and Chimeric Antigen Receptor (CAR) T-cell therapy.
- Vaccine-related therapies and immune checkpoint inhibitors.
- Future perspectives on cancer vaccines.

Guest Editors

Dr. Ruchi Roy

UICentre for Drug Discovery, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA

Dr. Sunil Singh

Department of Surgery, Division of Surgical Oncology, University of Illinois Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/190019

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).